ClinicalTrials.gg
CompletedNCT00964366Updated May 30, 2017Results posted

Study to Determine and Compare the Tolerance and Irritation Potential of Topical Acne Medications

A Phase 4 interventional study of clindamycin and benzoyl peroxide and Dapsone gel in Acne Vulgaris, sponsored by Stiefel, a GSK Company. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-05-30.

Sponsored by Stiefel, a GSK Company (part of GlaxoSmithKline) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
53
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing clindamycin in Acne Vulgaris — 1 open to participants now, 2 under way, none of them phase 3. Clindamycin · Acne Vulgaris.

Enrollment
23rd of 34
53 · median 117
Started
2009
with 7 others
Phase 4
16 of 34
1 open now
Registered
10th of 34
by date
Lead sponsor
10 of 34
Stiefel, a GSK Company

Among the 34 studies testing clindamycin in Acne Vulgaris, this one is the 23rd largest by enrollment, is one of 8 that started in 2009, is one of 16 in phase 4, and was the 10th registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

1 of the 34 studies testing clindamycin in Acne Vulgaris is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About clindamycin

Clindamycin: first FDA approval 1970 (CLEOCIN HYDROCHLORIDE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing clindamycin in Acne Vulgaris, or all of them as a file.
02

Study summary

This is a randomized, half-face study. On 1 side of the face, the subject will apply 1 of the 2 test products, clindamycin and benzoyl peroxide or dapsone gel and the contra lateral side of the face will remain non-treated to serve as a control.

Read the detailed description

This is a single-blind (blinded expert grader), parallel group, randomized, half-face study being conducted at one clinical site. On 1 side of the face, the subject will apply 1 of the 2 test products, clindamycin and benzoyl peroxide or dapsone gel and the contra lateral side of the face will remain non-treated to serve as a control. Approximately 25-30 male and female healthy subjects without facial acne, aged 18 to 45, will be randomly assigned to each product.

The eligible subjects who qualify will be entered into a 2-week treatment phase. The first of application of the study medication will be supervised at the site, Monday through Friday of each week. Any additional applications should be applied by the subjects at home each evening and the times of application recorded on a diary card. Subjects will apply the study product at home on Saturdays and Sundays and record the times of application on a diary card.

A blinded expert grader will rate comparative product tolerance during the study before study product is applied.

Instrumentation measurements of TEWL will be utilized to evaluate product mildness.

Duplicate sebum samples will be taken from the left and right forehead areas and assessed.

Subject will complete questionnaires and all adverse events will be recorded.

03

Conditions studied

  • Acne Vulgaris

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Capable of understanding and willing to provide signed and dated written voluntary (and any local or national authorization requirements) before any protocol specific procedures are performed.
  • Male and female subjects aged from 18 to 45 years at time of consent.
  • Has a Fitzpatrick Skin Type of I, II, or III.
  • Is willing to discontinue use of all facial products (other than the cleanser provided and makeup or razor and facial shave product) on the face for the 3 days before their baseline/day 0 visit and use only the provided facial products and their normal makeup or razor and facial shaving product for the duration of the study.
  • Is willing to not change brands of makeup or razor and facial shave product during the study.
  • Is willing to refrain from using any facial product on the face other than study products and their normal makeup or razor and facial shave product for the duration of the study.
  • Is willing to refrain from exercising prior to their instrument appointments.
  • Is willing to refrain from showering or drinking caffeinated beverages within 1 hour prior to their instrument visits.
  • Is willing to report to the site for each visit with a clean face and no makeup.
  • Is willing to avoid sunburn, tanning, tanning beds or other excessive sun exposure. Understands that if their skin tone changes significantly during the study it will be necessary to discontinue their participation.
  • Able to complete the study and to comply with study instructions.
  • Sexually active females of participating in the study must agree to use a medically acceptable method of while receiving protocol-assigned product. A woman of childbearing potential is defined as one who is biologically capable of becoming pregnant; including perimenopausal women who are less than 2 years from their last menses.

Exclusion criteria

Exclusion Criteria:

  • Female subjects who are pregnant, trying to become pregnant, or breast feeding.
  • Male subjects that have facial beards (mustache and/or goatee is acceptable).
  • Is a Type I diabetic.
  • Has active or chronic skin allergies.
  • Has a history of acute or chronic disease that might interfere with, or increase the risk of study participation.
  • Has participated in other facial studies in the preceding 30 days or other clinical studies in preceding 14 days.
  • Had skin cancer treatment in preceding 12 months.
  • Has damaged skin on facial areas (eg, from sunburn, tattoos, scars).
  • Had any medical procedure (e.g., laser resurfacing, chemical peels, plastic surgery) to facial areas in preceding 12 months.
  • Had any cosmetic procedure (e.g., microdermabrasion, etc.) to facial areas within 8 weeks of the baseline visit.
  • Use of topical retinoids or related agents for the treatment of acne or photoaging in the preceding 6 months.
  • Live in the same household as currently enrolled subjects.
  • Employees of investigator/clinical research organization (CRO) or Stiefel Laboratories involved in the study, or an immediate family member (partner, offspring, parents, siblings or sibling's offspring) of an employee involved in the study.
  • Any other condition or factor the investigator or his duly assigned representative believes may affect the skin response or the interpretation of the test results.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
53 participants (actual)

Study arms

  • Experimental
    Clindamycin/BPO gel

    Once-daily applications of clindamycin/BPO gel to the randomized side of the face either left or right.

    Drug: clindamycin and benzoyl peroxide

  • Active comparator
    Dapsone gel

    Twice-daily applications of dapsone gel to one side of the face.

    Drug: Dapsone gel

Interventions

  • Drugclindamycin and benzoyl peroxide

    Drug pages: Clindamycin · Benzoyl Peroxide

    Daily applications, to the randomized side of the face either left or right, of clindamycin and benzoyl peroxide

    Also known as: Duac® gel

  • Twice-daily applications of dapsone gel

    Also known as: ACZONE® (dapsone) Gel, 5%

06

What researchers measure

Primary outcomes

  1. Skin Erythema (Redness)

    Assessment of erythema as part of an evaluation of tolerance of two treatments: clindamycin and benzoyl peroxide or dapsone gel. This was done by visual assessment by an independent blinded grader using the grading scale shown below. Grade Description 0 None 2 Mild erythema 4 Moderate confluent erythema 6 Marked erythema with some edema 8 Marked erythema, edema, possible erosion

    Time frame: 2 Weeks

  2. Skin Dryness

    The amount of dryness on the left and right cheek of each panelist. The scale used to evaluate skin dryness is: Grade Description 0 None 2 Slight flaking 4 Moderate flaking/scaling 6 Marked scaling / slight fissuring 8 Severe scaling, fissuring Expert Grader assessments of dryness were taken prior to product application on Days 0, 1, 2, 3, 6, 7, 8, 9, 10, 13 and 14.

    Time frame: Baseline, Day 1through Day 14

Secondary outcomes

  1. Transepidermal Water Loss (TEWL)

    To assess skin moisture and hydration using transepidermal water loss (TEWL). These tables record the data obtained for each panelist at Baseline, and on Days 3, 7 and 14 or upon early termination of site(s), if applicable. Results are measured on a continuous scale.

    Time frame: 2 Weeks

  2. Sebum Measurements

    To sample the skin surface, the sebum collector strips are applied to the skin sites for 10 seconds. Once removed, these samples will be immediately measured for the amount of sebum on the strip using the tape analyzer. The amount of sebum production was measured as the amount of sebum collected on a tape applied to the skin for 10 seconds and then converted to 1 of 10 incremental levels. Sebum production was measured in increments of 0 (minimum value) to 10 (maximum value). The higher the number, the greater amount of sebum produced.

    Time frame: 2 weeks

  3. Skin Hydration

    Evaluation of Skin Hydration using electrical conductance measurements,on weekdays during 14 days of treatment. The value recorded which is expressed in units of microsiemens represents the AC conductance 2-3 seconds after placing the spring-loaded probe tip to the sample site.

    Time frame: 2 weeks

07

Results

Posted Apr 3, 2012

Participant flow

Clinical research center. Subject recruitment occurred from July 16, 2009 to Aug. 11, 2009

Participant flow — Overall Study
MilestoneClindamycin and BPO GelDapsone Gel
Started2825
Completed2724
Not completed11
Withdrew: Did not qualify at day 110
Withdrew: Withdrawal by subject01

Outcome measures

PrimarySkin Erythema (Redness)

Assessment of erythema as part of an evaluation of tolerance of two treatments: clindamycin and benzoyl peroxide or dapsone gel. This was done by visual assessment by an independent blinded grader using the grading scale shown below. Grade Description 0 None 2 Mild erythema 4 Moderate confluent erythema 6 Marked erythema with some edema 8 Marked erythema, edema, possible erosion

Time frame:
2 Weeks
Reported as:
Mean · Units on a scale
Skin Erythema (Redness)
Units on a scaleClindamycin and BPO GelDapsone Gel
Baseline1.06 ± 0.791.18 ± 0.63
Day 11.26 ± .761.34 ± .81
Day 21.55 ± .841.33 ± .85
Day 31.32 ± .631.50 ± .59
Day 61.30 ± .751.65 ± .92
Day 71.64 ± 1.021.53 ± .82
Day 81.80 ± .801.60 ± .93
Day 91.67 ± .951.45 ± .89
Day 101.81 ± .891.85 ± 1.13
Day 131.52 ± 1.201.65 ± 1.05
Day 142.10 ± 1.091.90 ± 1.15
Statistical analysis
  • Clindamycin and BPO Gel vs Dapsone Gel · Dunn's Multiple Comparisons Test · p = > 0.05
SecondaryTransepidermal Water Loss (TEWL)

To assess skin moisture and hydration using transepidermal water loss (TEWL). These tables record the data obtained for each panelist at Baseline, and on Days 3, 7 and 14 or upon early termination of site(s), if applicable. Results are measured on a continuous scale.

Time frame:
2 Weeks
Reported as:
Mean · TEWL rates (gm/m2/hr)
Transepidermal Water Loss (TEWL)
TEWL rates (gm/m2/hr)Clindamycin and BPO GelDapsone Gel
Baseline10.29 ± 3.0610.4 ± 2.93
Day 312.34 ± 4.8011.21 ± 3.26
Day 714.39 ± 3.7311.53 ± 3.09
Day 1413.88 ± 3.7011.26 ± 3.08
PrimarySkin Dryness

The amount of dryness on the left and right cheek of each panelist. The scale used to evaluate skin dryness is: Grade Description 0 None 2 Slight flaking 4 Moderate flaking/scaling 6 Marked scaling / slight fissuring 8 Severe scaling, fissuring Expert Grader assessments of dryness were taken prior to product application on Days 0, 1, 2, 3, 6, 7, 8, 9, 10, 13 and 14.

Time frame:
Baseline, Day 1through Day 14
Reported as:
Mean · Units on a scale
Skin Dryness
Units on a scaleClindamycin and BPO GelDapsone Gel
Baseline0.11 ± 0.320.12 ± 0.33
Day 10.04 ± 0.050.28 ± 0.71
Day 20.10 ± 0.260.23 ± 0.57
Day 30.16 ± 0.320.48 ± 0.81
Day 60.27 ± 0.790.37 ± 0.64
Day 70.21 ± 0.450.23 ± 0.47
Day 80.54 ± 1.030.17 ± 0.35
Day 90.5 ± 1.040.10 ± 0.20
Day 100.57 ± 0.910.15 ± 0.44
Day 130.57 ± 1.240.17 ± 0.45
Day 140.55 ± 1.110.12 ± 0.28
Statistical analysis
  • Clindamycin and BPO Gel vs Dapsone Gel · Dunn's Multiple Comparisons Test · p = < 0.05 (Dapsone versus Clindamycin/BPO gel.)
SecondarySebum Measurements

To sample the skin surface, the sebum collector strips are applied to the skin sites for 10 seconds. Once removed, these samples will be immediately measured for the amount of sebum on the strip using the tape analyzer. The amount of sebum production was measured as the amount of sebum collected on a tape applied to the skin for 10 seconds and then converted to 1 of 10 incremental levels. Sebum production was measured in increments of 0 (minimum value) to 10 (maximum value). The higher the number, the greater amount of sebum produced.

Time frame:
2 weeks
Reported as:
Mean · units on a scale
Sebum Measurements
units on a scaleClindamycin and BPO GelDapsone Gel
Baseline1.72 ± 1.312.18 ± 1.73
Day 31.52 ± 1.011.72 ± 1.11
Day 72.65 ± 2.053.33 ± 2.43
Day 142.35 ± 2.012.38 ± 1.67
Statistical analysis
  • Clindamycin and BPO Gel vs Dapsone Gel · ANOVA · p = >0.05
SecondarySkin Hydration

Evaluation of Skin Hydration using electrical conductance measurements,on weekdays during 14 days of treatment. The value recorded which is expressed in units of microsiemens represents the AC conductance 2-3 seconds after placing the spring-loaded probe tip to the sample site.

Time frame:
2 weeks
Reported as:
Mean · Microsiemens
Skin Hydration
MicrosiemensClindamycin and BPO GelDapsone Gel
Baseline499.51 ± 124.27448.31 ± 149.26
4 hours post 1st treatment430.38 ± 156.71404.68 ± 170.45
Day 3614.73 ± 144.64511.63 ± 163.97
Day 7460.65 ± 169.03456.73 ± 173.07
Day 14477.80 ± 173.40471.13 ± 194.77
Statistical analysis
  • Clindamycin and BPO Gel vs Dapsone Gel · ANOVA · p = >0.05

Adverse events

Collected over 14 days.. Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Clindamycin and BPO Gel—0/27 (0%)2/27 (7.4%)
Dapsone Gel—0/25 (0%)2/25 (8%)
Most frequent other events
Most frequent other events
EventClindamycin and BPO GelDapsone Gel
HeadacheNervous system disorders1/271/25
InfectionInfections and infestations1/271/25

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Clindamycin and BPO GelDapsone GelTotal
<=18 years213
Between 18 and 65 years262450
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)Clindamycin and BPO GelDapsone GelTotal
Female212243
Male7310
Region of Enrollment
Region of Enrollment(participants)Clindamycin and BPO GelDapsone GelTotal
United States282553
08

Study locations

1 site
  • cyberDERM
    Broomall, Pennsylvania 19008, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2009, a primary completion of Aug 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2012, 2 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2009
First posted
Aug 24, 2009
Start
Jul 2009
Primary completionActual
Aug 2009
CompletionActual
Aug 2009
Results first posted
Apr 3, 2012
Last update
May 30, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00964366
Collaborators
GlaxoSmithKline
Responsible party
Sponsor
First posted
Aug 24, 2009
Start date
Jul 2009
Primary completion
Aug 2009
Completion
Aug 2009
Results posted
Apr 3, 2012
Last update
May 30, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Clindamycin · Benzoyl Peroxide

Start the discussion